Trials / Completed
CompletedNCT03398083
Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam
A Human Abuse Potential Study to Evaluate the Subjective and Physiological Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam in an Inpatient Setting
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- National Institute on Drug Abuse (NIDA) · NIH
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the abuse potential of CBD to determine whether it should remain as a Schedule I drug under the Controlled Substances Act, or be recommended for decontrol.
Detailed description
This is a single-dose, randomized, double-blind, placebo- and active-controlled crossover study that evaluates CBD in comparison with THC, alprazolam, and placebo in healthy recreational drug users.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | THC | THC capsule |
| DRUG | Alprazolam | Alpraxolam capsule |
| DRUG | Placebo oral capsule | Sugar pill capsule |
| DRUG | CBD | CBD capsule |
Timeline
- Start date
- 2017-12-04
- Primary completion
- 2018-05-30
- Completion
- 2018-05-30
- First posted
- 2018-01-12
- Last updated
- 2018-06-14
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03398083. Inclusion in this directory is not an endorsement.